ADAR1 Capital reports 5.8% stake in Editas Medicine
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger report beneficial ownership of Editas Medicine, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger report beneficial ownership of Editas Medicine, Inc. common stock. Private investment funds managed by ADAR1 Capital Management hold 8,889,000 shares of Editas common stock, representing 5.8% of the class based on 153,530,898 shares outstanding as of June 30, 2026.
Both ADAR1 Capital Management and Mr. Schneeberger report shared voting and dispositive power over the 8,889,000 shares and no sole voting or dispositive power. Mr. Schneeberger files as a control person of ADAR1 Capital Management, which is characterized as an investment adviser. The filing is made jointly under a joint filing agreement.
Key Figures
Key Terms
beneficially owned financial
control person financial
investment adviser financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Editas Medicine (EDIT) does ADAR1 Capital Management report?
How was the 5.8% ownership in Editas Medicine (EDIT) calculated?
Who are the reporting persons in this Schedule 13G for Editas Medicine (EDIT)?
In what capacity does Daniel Schneeberger report Editas (EDIT) ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.